288 related articles for article (PubMed ID: 32733489)
1. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.
Stahel PF; Barnum SR
Front Immunol; 2020; 11():1661. PubMed ID: 32733489
[No Abstract] [Full Text] [Related]
2. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
3. Could severe COVID-19 be considered a complementopathy?
Chatzidionysiou K; Svenungsson E; Faustini F
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32430402
[No Abstract] [Full Text] [Related]
4. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
6. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
[TBL] [Abstract][Full Text] [Related]
7. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
8. The complement inhibitors in COVID-19: future expectations.
Korotchaeva Y; Kozlovskaya N; Bobrova L; Kamyshova E; Demyanova K; Moiseev S
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6480-6481. PubMed ID: 32633332
[No Abstract] [Full Text] [Related]
9. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
10. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
[TBL] [Abstract][Full Text] [Related]
11. Immune status could determine efficacy of COVID-19 therapies.
Cully M
Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
[No Abstract] [Full Text] [Related]
12. COVID-19 remedies.
Nat Biomed Eng; 2020 Jun; 4(6):575-576. PubMed ID: 32533125
[No Abstract] [Full Text] [Related]
13. Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
Abid MB; Mughal M; Abid MA
JAMA Oncol; 2020 Oct; 6(10):1529-1530. PubMed ID: 32433719
[No Abstract] [Full Text] [Related]
14. The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics.
Woodruff TM; Shukla AK
Trends Immunol; 2020 Nov; 41(11):965-967. PubMed ID: 33023856
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.
Bergmann CC; Silverman RH
Cleve Clin J Med; 2020 Jun; 87(6):321-327. PubMed ID: 32366502
[No Abstract] [Full Text] [Related]
16. [COVID-19: Swiftness and solidarity].
Moller AD
Laeknabladid; 2020 Jun; 106(6):289. PubMed ID: 32491989
[No Abstract] [Full Text] [Related]
17. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
18. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
Halstead SB; Akkina R
Front Immunol; 2020; 11():1196. PubMed ID: 32574267
[No Abstract] [Full Text] [Related]
19. SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners.
Biondi Zoccai G; Landoni G; Carnevale R; Cavarretta E; Sciarretta S; Frati G
Minerva Cardioangiol; 2020 Apr; 68(2):61-64. PubMed ID: 32150358
[No Abstract] [Full Text] [Related]
20. The "virtual wards" supporting patients with covid-19 in the community.
Thornton J
BMJ; 2020 Jun; 369():m2119. PubMed ID: 32499317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
